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ABSTRACT 
Myricetin belongs to the members of polyphenolic compounds that make up the flavonoid class, which possess antioxidant 
properties.   Myricetin is mostly obtained from vegetables, fruits, nuts, berries, tea, and is also found in red wine. It is also similar 
structurally to quercetin, fisetin and luteolin and is known to possess similar functions as the other members in the flavonol class 
of flavonoids. The health benefits of myricetin cuts across being an anticarcinogen compound to its antiviral, antithrombotic, 
antidiabetic, antiatherosclerotic, neuroprotective and anti-inflammatory properties among others. It also plays a role as a 
cyclooxygenase 1 inhibitor, an antineoplastic agent, an antioxidant, a plant metabolite, a food component and a hypoglycemic 
agent. It is a hexahydroxyflavone and a 7-hydroxyflavonol. The 2D structure of myricetin was obtained from the PubChem 
database while the MarvinSketch software was used to effect the various structural modifications on the compound. The structural 
modifications entails the substitution of the OH group attached to the C1 of myricetin with different functional groups such as 
the C=O, C2H5, CH3, CHO, CONH2, H and OCH3 which were saved as mrv files. The saved mrv files for each 2D structures 
were converted into canonical SMILES with the aid of the Open Babel software while the pharmacokinetic parameters for each 
compound was predicted using the SwissADME server. Results from this study showed that the C2H5, CH3 and H analogues of 
myricetin showed a higher gastrointestinal absorption rate compared to their C=O, CHO, CONH2 and OCH3 counterparts. This 
result shows that the C2H5, CH3 and H analogues of myricetin might be more orally bioavailable compared to myricetin and the 
other modified analogues. Preclinical studies on these compounds are therefore recommended 
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INTRODUCTION 
 
Bioavailabilityis used in the description of the fraction of 
anunchanged administered drug dose that gets to the systemic 
circulation, one of the drugs 
principal pharmacokinetic properties. Going by this 
definition, an intravenously administered drug possesses a 
100% bioavailability (Griffin, 1978). However, administering 
a medication through other routes (such as the oral 
administration) generally reduces the drug bioavailability (due 
to absorption and first-pass metabolism that remains 
incomplete) and this may also vary amidst patients. 
Bioavailability remains one of the basic essentials of 
pharmacokinetics, as the bioavailability properties of drug-
like compounds must be considered in dosage calculationsfor 
administration routes that are non-intravenous.In the case of 
herbs, dietary supplements and other nutrients where the route 
of administration is mostly oral, generally, the bioavailability 
simply refers to the ingested dose quantity or fraction that is 
absorbed  (Ong, and Khoo, 1997).The bioavailability 
definition for drugs is slightly different in comparison to 
the dietary supplements and this difference is due to the 
administration method coupled with thespecified regulations 
from the Food and Drug Administration (Heaney, 2001). 
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 Myricetin has a wide variety of effects in the body 
biologically (Ross and Kasum , 2002). Several studies have 
shown that it possess anti-cancer and antimutagenic properties 
and likewise has been implicated in the promotion of 
mutagenesis by utilizing the Ames Test (Mortelmans and 
Zeiger, 2000).The anti-inflammatory properties of this 
flavonoid were also discovered (Santhakumar et al., 2013). 
Myricetinin some other studies have been revealed to inhibit 
the tumor necrosis factor-alpha expression, a cytokine which 
aids the inflammatory response and is implicated in 
inflammatory diseases (Hollman and Katan, 1999). 
 Furthermore, myricetin consumption is good for the 
functionality of the heart (Flamini, 2013). Flavonoids like 
myricetin may improve the heart health through the prevention 
the oxidation of low density lipoproteins(LDL) and likewise 
reducing the oxidized LDL macrophages uptake. Myricetin 
improves the brain health and may offer benefits to people 
suffering from such brain diseases as the Parkinson and 
Alzheimer’s disease through the suppression of the ROS 
production caused by glutamate and reduced glutamate-
induced activation of caspase-3. Myricetin has also been 
shown to restore dopamine level in laboratory animals with 
induced Parkinsonism. It also has been shown to inihibit the 
formation of beta-amyloid fibril in Alzheimer’s disease 
patients (Gupta, 2014). 
 The aim of this study was to carry out an in silico 
pharmacokinetic study on myricetin and its monosubstituted 
analogues which were derived through the structural 
modification of myricetin with the basic objective of 
increasing the bioavailability of the drug-like compound.. 
 
MATERIALS AND METHODS 
 
Ligand preparation: The 2D structure of myricetin and its 
modified analogues were designed using the MarvinSketch 
software (Chen, 2005). All designed structures were 
downloaded and saved as mrv files in preparation for docking.  
 
 
File conversion: Saved mrv files from the ligand preparation 
process were converted into SMILES strings (Simplified 
Molecular Input-Line-Entry System) using the Open Babel 
Open Source Chemistry Toolbox. Open Babel, a chemical 
toolbox is designed to speak many of the languages of 
chemical data (Noel et al., 2011). It's an open and 
collaborative project allowing anyone to make searches, 
conversions, analysis, or storage data from molecular 
modeling, chemistry, solid-state materials, biochemistry, or 
related areas (Bultinck et al., 2002). 
 
Ligand minimization: Myricetin and its modified analogues 
were minimized using the UCSF Chimera software (Pettersen 
et al., 2004). UCSF Chimera is an extensible program 
for analyzing and interactively visualizing molecular 
structures and related data which include supramolecular 
assemblies, density maps, alignment of sequences, results 
from molecular docking trajectories and conformational 
ensembles Goddard et al., 2017). 
 
Visualization of atoms: Atoms making up myricetin and its 
modified analogues were visualized using the Pymol 
molecular visualizer (Zhu 2014). PyMOL is an open-source 
tool for model visualization and it is made available for 
utilization in structural biology (Salam et al., 2014). 
The Py aspect of the name of the software is a reference 
pointer that it is extensible and extends by the python 




2D Structure of myricetin and its analogues 
Figure 1 shows the 2D structure of myricetin as designed by 
the MarvinSketch software. Modifications that resulted into 
the derivatives of this compound were made through the 
substitution of the OH group attached to the C1 of myricetin 
with different functional groups such as the C=O, C2H5, CH3, 





Figure 1.  
The two dimensional (2D) 
structures of myricetin and 
its modified derivatives as 
designed using the 
MarvinSketch software. 
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Figure 2:  
3D structure of Myricetin showing all labeled atoms 
 
Table 1:  
Physicochemical properties, lipophilicity, solubility, pharmacokinetics and lipinski druglikeness of antifolate drugs, gedunin and its modified 
derivatives 














Formula C15H10O8 C16H12O9 C17H14O7 C16H1207 C16H10O8 C16H11NO8 C15H10O7 C16H12O8 
Molecular weight g/mol 318.24 348.26 330.29 316.26 330.25 345.26 302.24 332.26 
Num. H-Bond acceptors 8 9 7 7 8 8 7 8 
Num. H-Bond donors 6 6 5 5 5 6 5 5 
TPSA Å² 151.59 157.66 131.36 131.36 148.43 174.45 131.36 140.59 
Lipophilicity Consensus 
Log Po/w 
0.79 0.44 1.86 1.46 0.73 0.28 1.12 0.98 
Water Solubility Log S Soluble Soluble Moderately 
Soluble 
Soluble Soluble Soluble Soluble Soluble 
GI absorption Low Low High High Low Low High Low 
BBB permeant No No No No No No No No 
P-gp substrate No No No No No No No No 
CYP1A2 inhibitor Yes No Yes Yes Yes Yes Yes Yes 
CYP2C19 inhibitor No No No No No No No No 
CYP2C9 inhibitor No No No No No No No No 
CYP2D6 inhibitor No No Yes Yes No No Yes No 
CYP3A4 inhibitor Yes No Yes Yes No No Yes Yes 
















Synthetic accessibility 3.27 3.39 3.42 3.36 3.29 3.26 3.21 3.36 
 
Table 2 
Name of compounds, their chemical formulas and the canonical SMILES strings for each compound. 
Compounds Chemical Formula Canonical SMILES 
Myricetin C15H10O8 c1(cc(cc2c1c(=O)c(c(o2)c1cc(c(c(c1)O)O)O)O)O)O 
C=O Analogue C16H12O9 c1(cc(cc2c1c(=O)c(c(o2)c1cc(c(c(c1)O)O)O)O)O)C=O.O 
C2H5 Analogue C17H14O7 c1(cc(cc2c1c(=O)c(c(o2)c1cc(c(c(c1)O)O)O)O)O)CC 
CH3 Analogue C16H12O7 c1(cc(cc2c1c(=O)c(c(o2)c1cc(c(c(c1)O)O)O)O)O)C 
CHO Analogue C16H10O8 c1(cc(cc2c1c(=O)c(c(o2)c1cc(c(c(c1)O)O)O)O)O)C=O 
CONH2 Analogue C16H11NO8 c1(cc(cc2c1c(=O)c(c(o2)c1cc(c(c(c1)O)O)O)O)O)C(=O)N 
H Analogue C15H10O7 c1cc(cc2c1c(=O)c(c(o2)c1cc(c(c(c1)O)O)O)O)O 
OCH3 Analogue C16H12O8 c1(cc(cc2c1c(=O)c(c(o2)c1cc(c(c(c1)O)O)O)O)O)OC 
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The 3D structure of myricetin 
The 3D structure of myricetin was generated though the input 
of the canonical SMILES obtained from the OpenBabel 
conversion of the 2D structure of the compound into the 
Chimera visualizer. The “Build Structure” function of the 
Chimera visualizer was enacted to generate a 3D structure 
which was saved as a Mol2 file. The saved Mol2 file was 
viewed using the Pymol visualize and this same software was 
used in labeling and viewing each atom making up the 
compound.  
 
In Silico Pharmacokinetics 
Table 1 illustrates the specific pharmacokinetics and drug-
likeness parameters of each experimental compound while 
table 2 shows the result of the structural formula conversion 




The polar surface area (PSA), also known as the topological 
polar surface area (TPSA) of a molecule is defined as the sum 
of all polar atoms (oxygen and nitrogen), with the inclusion of 
the hydrogen atom attachments. The polar surface area is a 
metric that is often used in medicinal chemistry to optimize 
the cell permeation ability of drugs. Molecules with a PSA 
value higher than 140 angstroms squared are known to be 
poor in cell membrane penetration(Pajouhesh and Lenz, 
2005). For molecules to penetrate the blood–brain 
barrier (BBB) (in order to act on the central nervous 
systemreceptors), the value assigned to the polar surface area 
must be less than 90 angstroms squared(Hitchcock and 
Pennington, 2006).Myricetin and all its modified analogues 
(C=O, C2H5, CH3, CHO, CONH2, H and OCH3) might lack 
the blood-brain barrier permeation attributes as their TPSA 
values appeared lower than 130 angstroms 
 The partition coefficient between n-octanol and water (log 
Po/w) serves as the classical method for the description of 
lipophilicity. The diversity of the models backing the 
predictors will increase the accuracy in the prediction usingthe 
consensus log Po/w (Mannhold et al., 2009). The lipinski’s 
rule (Lipinski et al., 2001) was used as the drug likeness 
descriptor for the purpose of this study and the optimal 
lipophilicity range (Log Po/w) allowed should not exceed 5. 
The observation from the concensus lipophilicity column of 
table 1 shows that myricetin and all the analogues derived 
from it fall within the optimal lipophilicity range and as such 
can be regarded as drug-like compounds.  
 Activities regarding drug development can be facilitated 
and made easier in cases where molecules are soluble. This 
brings about ease in drug handling and its formulation (Ritchie 
et al., 2013). Moreover, for discovery projects that target the 
oral form of administration, one of the major absorption 
property influencers is the solubility of the compound 
(Ottaviani, 2010). Also, drugs that are designed for parenteral 
administration requires a high solubility attribute to aid the 
delivery of an appreciable amount of the active ingredient in 
smaller volumes of pharmaceutical dosage (Savjani, 2012). A 
compound can be considered as soluble if the Log S value is 
less than 6 (Ritchie et al., 2013). Myricetin and its modified 
analogues used for the purpose of this study, according to the 
column projecting the solubility result in table 1 are all water 
soluble, implying that lipophilic compounds are absorbed 
more easily. 
The nature of the gastrointestinal mucosal membrane surface 
area plays an important role in the process of drug absorption 
and has a varying and differential effect from the stomach to 
the rectum. The physiochemical properties of the luminal 
content are also implicated to have an influence in drug 
absorption process (Bogentoft et al., 1978). The absorption 
process itself is continually described in terms of hypothesis 
of simple partition of pH, where absorption is controlled by 
the equilibrium position between the ionized and non-ionized 
forms of the drug at varying physiological pH values 
encountered in the gastrointestinal tract (Borgstroem et al., 
1957).As displayed in table 1, only the C2H5, CH3 and H 
analogues of myricetin showed attributes of high 
gastrointestinal absorption which is a pointer to their oral 
bioavailability properties. 
Overcoming the ability of a non-neuroactive drug to cross the 
blood brain barrier is a major challenge to be solved in the 
processes of designing drugs. Only neuroactive drugs are 
required to possess the blood brain permeation attribute for 
functionality On the contrary, non-neuroactive drugs should 
not cross the blood brain barrier for the avoidance of 
psychotropic side effects (Wolak and Thorne, 2013). Blood-
brain barrier permeation results from table 1 showed that none 
of the experimental ligands can penetrate the blood brain 
barrier.  
 The P-glycoprotein (P-gp) is involved physiologically in 
the reduction of the harmful effects of toxic compounds, 
xenobiotics and drugs which the body is exposed to by 
constantly pumping them out of cells. The need for the role 
played by the P-glycoprotein has led to the recognition of the 
modulation it confers on many important and clinical 
therapeutic agents and this pharmacokinetic importance has 
led to the incorporation of its screening in any process 
involving drug discovery (Wolak and Thorne, 2013). Drug 
pharmacokinetic parameters can also be affected through 
various drug induced induction or inhibition directed at 
modulating drug transporters and this can lead to a significant 
drug-drug interaction (Williams and Sinko, 1999).Myricetin 
and all its analogues appeared to be no substrates to the P-
glycoprotein hence their oral bioavailability remains intact.  
 The bioavailability of drugs designed for oral 
administration can be determined by the biotransformation 
process mediated by the intestinal CYP3A4and the constant 
pumping of absorbed drugs out of the cell which is a process 
mediated by the P-glycoprotein. It has been hypothesized that 
the action of the CYP3A4 and P-glycoprotein may be in 
concert to reduce oral drug bioavailability and viewing this 
hypothesis from a theoretical point of view makes it more 
attractive (Williams and Sinko, 1999). The recent test on the 
hypothesis of the possibility of the enhancement of substrate 
disappearance mediated by the CYP3A4 being stimulated by 
drugs interacting with the apical efflux pump suggests that the 
P-gp/CYP3A4 are cosubstrates and that P-glycoprotein 
increases the potentials of CYP3A4-mediated disappearance 
of drugs during secretary detoxification in the intestine (Chan 
et al., 2004). It is also possible for the P-glycoprotein to have 
an influence on first-pass metabolism in a manner describing 
co-operativity (Chan et al., 2004). Table 1 showed that the 
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C2H5, CH3, H, OCH3 analogues with the inclusion of 
myricetin are inhibitors of CYP3A4 which implies that they 
are likely to be orally bioavailable compared to the other 
experimental ligands which might undergo CYP3A4-
mediated intestinal biotransformation and in turn lowers their 
bioavailability.  
 Many areas in the process of drug discovery are in need of 
estimation models and methods for the determination of the 
ease of synthesizing drug-like molecules (synthetic 
accessibility).. The assessment of the synthetic accessibility 
(SA) of a lead candidate is a task which takes part in the 
discovery of lead, disregarding methods the lead candidate has 
been known with. The synthetic accessibility score ranges 
from 1 (very easy) to 10 (very difficult) after normalization 
process (Ertl, and Schuffenhauer, 2009). This confirms the 
ease of the laboratory synthesis myricetin and all its modified 
analogues as their synthetic accessibility score do not exceed 
4.0. 
 In conclusion, results from the in silico pharmacokinetics 
study on each of the experimental compounds have shown that 
the monosubstitution approach geared towards the 
improvement of the oral bioavailability of myricetin through 
structural modification is a reliable procedure. The C2H5, CH3 
and H analogues of myricetin have been shown to exhibit 
higher gastrointestinal absorption characteristics compared to 
other experimental ligands and as such might exhibit higher 
oral bioavailability tendencies. 
 We have also been able to observe that the 
monosubstituted groups that displayed the desired 
gastrointestinal absorption properties according to the in silico 
pharmacokinetics study were without oxygen. It can as such be 
inferred that the oxygen atom of the myricetin OH group might 
be implicated for its low gastrointestinal absorption attribute, 
likewise other modified functional groups with the oxygen 
moiety.The laboratory synthesis of the 3 compounds that has 
shown the desired GI absorption traits is therefore suggested 
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